Research programme: CD26 antigen antagonists - MGI GP

Drug Profile

Research programme: CD26 antigen antagonists - MGI GP

Latest Information Update: 20 Feb 2008

Price : $50

At a glance

  • Originator MGI GP
  • Class Azetidines
  • Mechanism of Action CD26 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Psychiatric disorders

Most Recent Events

  • 31 Dec 2007 Discontinued - Preclinical for Psychiatric disorders in USA (unspecified route)
  • 28 Oct 2005 Guilford Pharmaceuticals is now called MGI GP Inc
  • 05 Oct 2005 Guilford Pharmaceuticals has been acquired by MGI Pharma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top